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ABSTRACT 1 
 2 
Recent epigenome-wide association studies in Alzheimer’s disease have highlighted 3 
consistent robust neuropathology-associated DNA hypermethylation of the Ankyrin 1 4 
(ANK1) gene in the cortex. The extent to which altered ANK1 DNA methylation is 5 
also associated with other neurodegenerative diseases is not currently known. In the 6 
current study, we used bisulfite pyrosequencing to quantify DNA methylation across 7 
eight CpG sites within a 118bp region of the ANK1 gene across multiple brain 8 
regions in Alzheimer’s disease, Vascular dementia, Dementia with Lewy bodies, 9 
Huntington’s disease and Parkinson’s disease. We demonstrate disease-associated 10 
ANK1 hypermethylation in the entorhinal cortex in Alzheimer’s disease, Huntington’s 11 
disease and Parkinson’s disease, whilst in donors with Vascular dementia and 12 
Dementia with Lewy bodies we observed elevated ANK1 DNA methylation only in 13 
individuals with co-existing Alzheimer’s disease pathology. We did not observe any 14 
disease-associated differential ANK1 DNA methylation in the striatum in Huntington’s 15 
disease, or the substantia nigra in Parkinson’s disease. Our data suggests that ANK1 16 
is characterized by region and disease-specific differential DNA methylation in 17 
multiple neurodegenerative diseases. 18 
 19 
 20 
Keywords:  21 
Alzheimer’s disease (AD); Ankyrin 1 (ANK1); Brain; Dementia with Lewy Bodies 22 
(DLB); DNA methylation (5-methylcytosine – 5mC); Epigenetics; Huntington’s 23 
disease (HD); Parkinson’s disease (PD); Vascular dementia (VaD) 24 
 25 
 26 
 27 
 28 
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1. INTRODUCTION 1 
 2 
Dementia encompasses a group of chronic neurodegenerative diseases that affected 3 
an estimated 46.8 million people worldwide in 2015 (Wimo et al., 2017), of which 4 
Alzheimer’s disease (AD) accounts for ~60% of cases. The etiology of AD has been 5 
hypothesized to involve epigenetic mechanisms (Lunnon and Mill, 2013). In 2014 two 6 
epigenome-wide association studies (EWAS) of AD identified significant 7 
hypermethylation of CpG sites in the Ankyrin 1 (ANK1) gene associated with 8 
neuropathology in AD cortex (De Jager et al., 2014; Lunnon et al., 2014), which has 9 
been replicated in multiple independent study cohorts (Smith, 2017). Subsequently, a 10 
genome wide association study (GWAS) of a Han Chinese population identified a 11 
single-nucleotide polymorphism (SNP) in ANK1 associated with an increased 12 
susceptibility for developing AD (Chi et al., 2015). ANK1 links integral membrane 13 
proteins to the underlying spectrin-actin cytoskeleton and plays a key role in cell 14 
motility, activation, proliferation, contact, and maintenance of specialized membrane 15 
domains (Yang et al., 2011). There is now increasing interest in understanding the 16 
role of epigenetic changes in ANK1 in the development and progression of AD. One 17 
important question to be addressed is whether ANK1 hypermethylation is specific to 18 
AD, or observed in other neurodegenerative disorders. Although AD accounts for 19 
~60% of dementia cases, many other dementias share common symptoms and/or 20 
pathological hallmarks with AD.   21 
 22 
This study aimed to quantify DNA methylation levels across a 118bp region of ANK1, 23 
previously associated with AD, in a number of different neurodegenerative diseases. 24 
Using bisulfite pyrosequencing we assessed ANK1 DNA methylation in brain 25 
samples from donors with AD, Dementia with Lewy bodies (DLB), Vascular dementia 26 
(VaD), Huntington’s disease (HD), Parkinson’s disease (PD) and non-demented 27 
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elderly controls, across a number of different brain regions that are characterized by 1 
disease-specific pathology.  2 
 3 
 4 
2. MATERIALS AND METHODS 5 
 6 
2.1. Subjects and Samples  7 
Post-mortem brain tissue was obtained from six different UK brain banks (the South 8 
West Dementia Brain Bank (SWDBB), the London Neurodegenerative Disease Brain 9 
Bank (LNDBB) the Manchester Brain Bank, the Oxford Brain Bank, the Cambridge 10 
Brain Bank and the Newcastle Brain Bank). In total, tissue was obtained from 60 AD 11 
(Braak V-VI), 119 DLB, 27 VaD, 22 HD, 36 PD and 105 elderly non-demented control 12 
subjects (Braak 0-II). A subset of DLB (N = 39) and VaD (N = 5) cases also had co-13 
existing AD pathology. For each disease we analyzed the entorhinal cortex (EC), 14 
superior temporal gyrus (STG) and cerebellum (CER). For HD cases we also 15 
analyzed the striatum (STR) as this is primarily affected in disease (Reiner et al., 16 
2011), whilst for PD cases we analyzed the STR and substantia nigra (SN) as these 17 
are regions of pathology in this disease (Fearnley and Lees, 1991). For control 18 
samples we analyzed all five brain regions. For a small number of donors tissue was 19 
not available from all brain regions. Genomic DNA was isolated from ~100mg of each 20 
dissected brain region using a standard phenol-chloroform extraction method, and 21 
tested for degradation and purity prior to analysis as previously described (Smith et 22 
al., 2016). Demographic information for samples can be found in Supplementary 23 
Table 1. 24 
 25 
2.2. ANK1 bisulfite pyrosequencing  26 
Bisulfite pyrosequencing was used to quantify DNA methylation across eight 27 
individual CpG sites in the ANK1 gene, spanning from 41519302 to 41519420 within 28 
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chromosome 8 (hg19). Bisulfite conversion was performed using the Bisulfite-Gold kit 1 
(Zymo research, USA). A single amplicon (246bp) was generated using primers 2 
designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) as previously 3 
described (Lunnon et al., 2014). Pyrosequencing was performed using two 4 
sequencing primers to maximize coverage across eight CpG sites. DNA methylation 5 
was quantified using the Pyromark Q24 system (Qiagen, UK) following the 6 
manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software.  7 
 8 
2.3. Data Analysis  9 
All computations and statistical analyses were performed using R 3.3.2 (R 10 
Development Core Team, 2012). A linear regression analysis was performed, 11 
controlling for the effects of age, gender and batch effects, comparing control 12 
samples with samples affected by each neurodegenerative disease. For the VaD and 13 
DLB samples we also performed a second analysis to investigate whether co-existing 14 
AD pathology influenced the results by comparing individuals with and without co-15 
existing AD pathology to control samples, again accounting for the effects of age, 16 
gender and batch. Our analyses examined DNA methylation differences at (a) 17 
individual CpG sites and (b) averaged across the amplicon. We used a paired two-18 
tailed t-test to compare adjusted DNA methylation differences in disease across brain 19 
regions. 20 
 21 
 22 
3. RESULTS 23 
 24 
3.1. AD-associated ANK1 DNA hypermethylation is seen across all tissues 25 
analyzed 26 
First, we sought to replicate previous findings of ANK1 DNA hypermethylation in AD. 27 
Across the 118bp region, we observed significantly increased levels in AD cases 28 
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compared to controls in all eight ANK1 CpG sites in the EC (Figure 1A) and seven 1 
ANK1 CpG sites in the STG (Figure 1B). Both the EC and STG exhibit a high degree 2 
of AD pathology, even in the earliest stages of disease, with the EC being the starting 3 
point of AD pathology in the cortex with pathology seen here in Braak stage II (Braak 4 
and Braak, 1991). Conversely, the CER remains free of AD pathology until the very 5 
last stages of the disease, although even then this is limited to amyloid beta (Aβ) 6 
plaques with an absence of neurofibrillary tangles (NFTs) of hyperphosphorylated tau 7 
(Braak et al., 1989). Of note, we observed significant ANK1 DNA hypermethylation at 8 
five ANK1 CpG sites in the CER (Figure 1C). This is the first time ANK1 DNA 9 
methylation changes have been reported in the CER. Interestingly, two of the loci 10 
that did not display AD-associated ANK1 hypermethylation in the CER were 11 
chr8:41519308 and chr8:41519399, the two sites included on the Illumina 450K array 12 
used in previous EWAS analyses of AD which did not identify ANK1 13 
hypermethylation in AD in the CER (Lunnon et al., 2014). Average DNA methylation 14 
across the amplicon region was significantly elevated in AD in the EC (P = 1.29 x 10-15 
07), STG (P = 2.39 x 10-03) and CER (P = 7.81 x 10-03) (Figure 1D). ANK1 DNA 16 
methylation differences between cases and controls at both individual sites and 17 
across the amplicon were lower in the CER compared to other tissues tested 18 
(Supplementary Table 2), with a significantly greater DNA methylation difference 19 
between cases and controls in the EC (amplicon average corrected DNA methylation 20 
difference (∆) = 4.53%) compared to both the STG (amplicon average ∆ = 2.84%; P 21 
= 7.98 x 10-4) and the CER (amplicon average ∆ = 1.17%, P = 2.55 x 10-4). 22 
Interestingly, this pattern of change matches the spread of AD pathology throughout 23 
the brain.  24 
 25 
3.2. ANK1 DNA hypermethylation in the EC is only observed in DLB cases 26 
with co-existing AD pathology 27 
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DLB is the third most common cause of dementia with the age of onset ranging from 1 
50 to 83 years (McKeith, 2002). The pathology of DLB shares similarities to AD, with 2 
the presence of immune regulation and microglial activation being consistent 3 
between diseases (Mackenzie, 2000). However, the presence of Lewy bodies within 4 
the brain makes DLB considerably more comparable to PD (McKeith, 2002). In fact, 5 
PD dementia is thought to be biologically identical to DLB, only differing in the order 6 
in which the motor or cognitive symptoms occur (Dodel et al., 2008). Interestingly we 7 
observed significant hypermethylation of ANK1 in DLB cases compared to controls in 8 
the EC (Figure 2A) at four of the eight ANK1 CpG sites (Supplementary Table 3). 9 
We saw no difference between DLB and control samples in either the STG 10 
(Supplementary Figure 1A) or the CER (Supplementary Figure 1B) at any of the 11 
eight ANK1 CpG sites. Across the ANK1 amplicon we observed significant DLB-12 
associated hypermethylation in the EC (P = 0.0244), but not in the STG or CER (P > 13 
0.05) (Figure 2B). It is widely reported that DLB and AD frequently co-occur 14 
(Rosenberg et al., 2001); we were therefore interested to investigate whether we still 15 
observed DLB-associated DNA hypermethylation in the EC when we controlled for 16 
co-existing AD pathology. We found no significant changes in ANK1 DNA 17 
methylation in individuals with “pure” DLB compared to controls in the EC (Figure 18 
2C), STG (Supplementary Figure 1C) and CER (Supplementary Figure 1D). 19 
However, we did observe significant hypermethylation in DLB cases with co-existing 20 
AD pathology compared to controls at seven of the eight ANK1 CpG sites in the EC 21 
(Figure 2C) and two sites in the STG (Supplementary Figure 1C), with no 22 
difference in the CER (Supplementary Figure 1D). When we looked across the 23 
whole 118bp region, we saw increased ANK1 DNA methylation in the EC in 24 
individuals with co-existing AD pathology (P = 1.45 x 10-03) (Figure 2D), suggesting 25 
that the ANK1 hypermethylation seen in some individuals with DLB is primarily driven 26 
by AD pathology.  27 
 28 
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3.3.  ANK1 hypermethylation is seen in the EC only in VaD individuals with 1 
co-existing AD pathology 2 
Characterized by the loss of neurological function due to ischemic events, the risk of 3 
developing VaD is closely linked to vascular health (Román et al., 1993). We 4 
observed increased DNA methylation in individuals with VaD at none of the ANK1 5 
CpG sites in the EC (Figure 3A), only one site in the STG (Supplementary Figure 6 
2A) and no sites in the CER (Supplementary Figure 2B) (Supplementary Table 4), 7 
with no difference across the amplicon in any of the brain regions tested (P > 0.05) 8 
(Figure 3B). Because VaD also often co-occurs with AD we next examined whether 9 
stratifying cases by the presence of AD pathology altered these findings. 10 
Interestingly, we saw disease-associated hypermethylation in the EC at five of the 11 
eight ANK1 CpG sites only in individuals with co-existing AD pathology (Figure 3C), 12 
whilst we saw disease-associated hypomethylation at one site in the STG 13 
(Supplementary Figure 2C) in individuals with “pure” VaD, and no disease-14 
associated changes in the CER (Supplementary Figure 2D).  When we looked 15 
across the 118bp region we only saw significant ANK1 hypermethylation in 16 
individuals with VaD and co-existing AD pathology compared to controls in the EC (P 17 
= 0.0163) (Figure 3D). It is worth noting that our cohort only had a small number of 18 
VaD cases with co-existing AD pathology (N=5). 19 
 20 
3.4. ANK1 DNA hypermethylation in the EC is seen in both HD and PD. 21 
HD is characterized by a trinucleotide repeat in the huntingtin gene (HTT). The 22 
abundance of the repeat is proportional to the level of protein misfolding and 23 
downstream cytosolic accumulation, leading to neuronal cell death and the 24 
symptoms of HD (Walker, 2007).  ANK1 DNA hypermethylation was seen at four of 25 
the eight CpG sites in the EC in HD (Figure 4A). However, no differential DNA 26 
methylation was seen in the other brain regions tested (Supplementary Table 5), 27 
including the STG (Supplementary Figure 3A), the CER (Supplementary Figure 28 
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3B) and the STR (Supplementary Figure 3C), a region that forms part of the basal 1 
ganglia, known to be the first brain region to be adversely affected by HD pathology 2 
(Walker, 2007). Averaging across the region again highlighted significant 3 
hypermethylation in the EC (P = 6.68 x 10-3), with no significant change in any other 4 
tissue (Figure 4B).   5 
 6 
A similar pattern of ANK1 hypermethylation was observed in PD; two of the eight 7 
CpG sites were characterized by significant hypermethylation in the EC (Figure 4C), 8 
with no differences in DNA methylation in any of the other brain regions tested 9 
(Supplementary Table 6). This included the STG (Supplementary Figure 4A), the 10 
CER (Supplementary Figure 4B), the STR (Supplementary Figure 4C) and the SN 11 
(Supplementary Figure 4D), with the SN representing the brain region that has the 12 
highest levels of pathology in PD (Fearnley and Lees, 1991). Across the 118bp 13 
amplicon we saw no change in DNA methylation in any of the five brain regions 14 
(Figure 4D).  15 
 16 
 17 
4. DISCUSSION 18 
 19 
This is the first study to assess brain ANK1 DNA methylation changes across 20 
multiple neurodegenerative diseases. We identified significant DNA methylation 21 
changes in the EC in multiple diseases, including AD, HD and PD, with significant 22 
DNA hypermethylation across the amplicon in AD and HD. Interestingly, we also 23 
observed significant hypermethylation of ANK1 in the EC in both DLB and VaD at 24 
several individual CpG sites and across the amplicon, but only in donors with co-25 
existing AD pathology. This suggests that ANK1 DNA hypermethylation in the EC is 26 
specific to some neurodegenerative diseases (AD, HD and to some extent PD), and 27 
not observed in other forms of neuropathology (VaD and DLB). Although it is possible 28 
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that the observed changes in ANK1 could reflect a common feature of 1 
neurodegenerative diseases, such as neuroinflammation, it is worth noting that we 2 
did not observe ANK1 DNA hypermethylation in all diseases, for example we did not 3 
see any hypermethylation in individuals with “pure” DLB or VaD. These diseases are 4 
also characterised by neuroinflammation, so this suggests that the observed 5 
hypermethylation does not simply reflect a common hallmark of all 6 
neurodegenerative diseases such as microgliosis. We have previously reported that 7 
ANK1 is not hypermethylated in the CER in AD at two sites interrogated by the 8 
Illumina 450K array (chr8:41519308 and chr8:41519399). In the current study we 9 
again demonstrate that these two loci are not significantly differentially methylated in 10 
AD; however, we do highlight AD-associated DNA hypermethylation at five adjacent 11 
CpG sites and averaged across the 118bp amplicon in the CER. We did not see any 12 
ANK1 DNA methylation changes in the CER in any of the other neurodegenerative 13 
diseases, including those with co-existing AD pathology. Reflecting our previous 14 
findings, we found that DNA methylation differences in AD are greatest in the EC, an 15 
area with high levels of neuropathology and lowest in the CER, the region with the 16 
least neuropathology. Interestingly, although we observed disease-associated ANK1 17 
hypermethylation in the EC at six individual sites and across the region in HD and at 18 
two individual sites in PD, we did not see ANK1 DNA methylation changes in these 19 
diseases in their regions of primary neuropathology, namely the STR and SN, 20 
respectively. This suggests that ANK1 hypermethylation in neurodegenerative 21 
disease is not necessarily specific to regions of primary neuropathology, but may 22 
instead be specific to particular cell types affected in only specific diseases, such as 23 
those in the EC, which are not present in the STR and SN. ANK1 encodes for 24 
numerous isoforms with their own tissue-specific enhancers. Although the precise 25 
function of most ANK1 isoforms is not known, different isoforms have been identified 26 
in the brain, blood and muscle (Gallagher et al., 1997). It would be of interest to 27 
examine expression levels of different ANK1 transcript variants, to facilitate the 28 
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interpretation of the DNA methylation differences we observe. Mastroeni et al., 1 
recently showed a four-fold increase in ANK1 mRNA expression in microglia from AD 2 
brain tissue, but not in neurons or astrocytes from the same individuals, suggesting 3 
an immune based function for ANK1 in the human brain (Mastroeni et al., 2017). One 4 
potential caveat of our study is that we have analyzed “bulk” tissue, and we cannot 5 
determine which cell type(s) are driving the DNA hypermethylation seen in ANK1 in 6 
disease.  7 
 8 
Although the focus of our study was on investigating DNA methylation changes in 9 
disease, bisulfite pyrosequencing actually generates a summative measurement of 10 
both DNA methylation and DNA hydroxymethylation. DNA methylation is generally 11 
associated with gene silencing, particularly when residing in the promoters of 12 
constitutively expressed housekeeping genes (Jones, 2012), whilst DNA 13 
hydroxymethylation has been shown to be enriched in gene bodies (Lunnon et al., 14 
2016) and to be found at (relatively) high levels in the brain (Khare et al., 2012; 15 
Szulwach et al., 2011). We have recently shown that ANK1 DNA hypermethylation 16 
across the 118bp amplicon in AD is actually underestimated when using bisulfite 17 
data, as it is confounded by significant DNA hypohydroxymethylation at some loci in 18 
the amplicon (Smith et al., Under Review). Another caveat to our study is that we 19 
have only analyzed DNA methylation across eight CpG sites in a 118bp region of the 20 
ANK1 gene and thus future studies should aim to further quantify changes in DNA 21 
methylation across the entire 244kb gene.  22 
 23 
5. CONCLUSIONS 24 
 25 
Our study has demonstrated disease-associated ANK1 hypermethylation in the EC at 26 
specific CpG sites in AD, HD and PD and across the region in AD and HD. In donors 27 
with DLB and VaD we only observed increased ANK1 DNA methylation in the EC in 28 
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individuals with co-existing AD pathology. The CER showed disease-associated 1 
hypermethylation at specific CpG loci and across the region in AD, but not in any of 2 
the other neurodegenerative diseases tested. We saw no disease-associated 3 
differential ANK1 DNA methylation in the STR in HD or PD, or the SN in PD. This 4 
suggests that ANK1 is characterized by brain region and disease-specific differential 5 
DNA methylation in different neurodegenerative diseases. It is unlikely that the 6 
identified DNA methylation changes in ANK1 could be useful as a biomarker 7 
clinically, as we have previously shown that ANK1 is not hypermethylated in blood in 8 
AD(Lunnon et al., 2014). However, these epigenetic changes could represent novel 9 
therapeutic targets for disease, if shown to be causal in pathology. At present we are 10 
unable to determine whether these changes represent a cause or a consequence of 11 
the disease process. Further functional studies should therefore be performed to 12 
determine the potential disease causality of this modification.  13 
 14 
 15 
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Figure 1: ANK1 is hypermethylated in the EC, STG and CER in AD brain. Using bisulfite
pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 41519302 to
41519420 on chromosome 8 (genome build hg19) in (A) EC, (B) STG and (C) CER tissue. in
AD samples (Braak V-VI) compared to control samples (Braak 0-II). We demonstrated
significant neuropathology-associated hypermethylation at all assayed CpG sites in the EC,
significant hypermethylation at seven of the eight CpG sites in the STG and five of the eight
sites in the CER. (D) When data was summed across the 118bp amplicon region we
observed a significant increase in DNA methylation across all brain regions (EC: P = 1.29 x
10-7, STG: P = 2.39 x 10-3 and CER: P = 7.81 x 10-3). Data is represented as mean (±SEM)
Key: *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 2: ANK1 hypermethylation is observed in the EC in individuals with DLB and co-
existing AD pathology. Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1
gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in all DLB
samples compared to control samples. (A) We demonstrated significant neuropathology-associated
hypermethylation at four CpG sites in the EC. (B) When data was summed across the 118bp
amplicon region we observed a significant increase in DNA methylation in the EC (P = 0.024). Some
individuals with DLB also had co-existing AD pathology; (C) when we compared DNA methylation
levels in ANK1 in individuals with DLB and co-existing AD pathology, or individuals with “pure” DLB
only to controls, we found significant hypermethylation at seven sites in the EC in individuals with co-
existing AD pathology. (D) When we averaged methylation across the region we saw significant
hypermethylation in the EC in individuals with co-existing AD pathology (P = 0.001). Data is
represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 3: ANK1 hypermethylation is observed in the EC in individuals with VaD and co-
existing AD pathology. Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1
gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in all VaD
samples compared to control samples. (A) We found no disease-associated differential methylation
at any individual sites in the EC, (B) nor any difference when averaged across the amplicon (B).
Some individuals with VaD also had co-existing AD pathology; (C) when we compared DNA
methylation levels in ANK1 in individuals with VaD and co-existing AD pathology, or individuals with
“pure” VaD only to controls, we found significant hypermethylation at five sites in the EC in
individuals with co-existing AD pathology. (D) When we averaged methylation across the region we
observed significant hypermethylation in the EC in individuals with a co-diagnosis of AD (P = 0.016).
Data is represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 4: ANK1 DNA methylation patterns in HD and PD. Using bisulfite pyrosequencing we
assayed a 118bp region of the ANK1 gene ranging from 41519302 to 41519420 on chromosome 8
(genome build hg19) in HD and PD samples compared to control samples. In HD donors in the EC
we observed neuropathology-associated hypermethylation at five sites (A) and significant
hypermethylation when we averaged methylation across the region (P = 0.007) (B). In PD donors in
the EC we found neuropathology-associated hypermethylation at two sites (C), but no significant
difference when we averaged across the region (D). Data is represented as mean (±SEM) Key: *P <
0.05, **P < 0.01, ***P < 0.005.
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HIGHLIGHTS 
 
 
 
 
• We analysed brain DNA methylation levels across a 118bp region of the ANK1 gene 
 
• We looked in multiple neurodegenerative diseases compared to controls 
 
• DNA hypermethylation was seen in the entorhinal cortex in AD, HD and PD 
 
• DNA hypermethylation in DLB and VaD was only in donors with co-existing AD 
 
• No disease-associated changes were seen in regions of primary pathology in HD or 
PD 
